Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for sleep disturbances in Parkinson's disease
NCT02768077Phase 4Unknown
- Sponsor
- Kuhnil Pharmaceutical
- Start
- Jan 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in Parkinson's disease (PD) comparing Melatonin with Placebo (2 arms). Primary endpoint: Pittsburgh Sleep Quality Index at 4 weeks. Status: unknown.
02
Drugs
melatonin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02768077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768077.